News
Important Only
FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness
July 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O:FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESSBRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALSReuters
Tue, Jul 8
Honeywell To Evaluate Strategic Alternatives For Productivity Solutions And Services And Warehouse And Workflow Solutions Businesses
July 8 (Reuters) - Honeywell International Inc HON.O:HONEYWELL TO EVALUATE STRATEGIC ALTERNATIVES FOR PRODUCTIVITY SOLUTIONS AND SERVICES AND WAREHOUSE AND WORKFLOW SOLUTIONS BUSINESSESHONEYWELL INTERNATIONAL INC - TO EVALUATE STRATEGIC ALTERNATIVES FOR PSS AND WWSHONEYWELL INTERNATIONAL INC - TO BE...Reuters
Tue, Jul 8
Dri Healthcare Comments On FDA Approval And Our Increased Investment In Kalvista Pharmaceuticals' Ekterly®
July 8 (Reuters) - Dri Healthcare Trust DHT_u.TO:DRI HEALTHCARE COMMENTS ON FDA APPROVAL AND OUR INCREASED INVESTMENT IN KALVISTA PHARMACEUTICALS' EKTERLY® (SEBETRALSTAT)Further company coverage: [DHT_u.TO]Reuters
Tue, Jul 8
Eupraxia Doses First Patient In Phase 2B Placebo-Controlled Portion Of Ep-104GI Resolve Trial
July 8 (Reuters) - Eupraxia Pharmaceuticals Inc EPRX.TO:EUPRAXIA DOSES FIRST PATIENT IN PHASE 2B PLACEBO-CONTROLLED PORTION OF EP-104GI RESOLVE TRIAL IN EOSINOPHILIC ESOPHAGITISEUPRAXIA PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 2B STUDY EXPECTED BY Q3 2026Reuters
Tue, Jul 8
Morning News Call - U.S., July 8
To access a PDF version of this newsletter, please click here You can read Morning News Call -- US via TOPNEWS U.S. Companies page.If you would like to receive this newsletter through your email, please register at:https://solutions.lseg.com/MorningNewsCallEN-subscription-page For Morning Ne...Reuters
Tue, Jul 8
Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug
July 8 (Reuters) - Upstream Bio Inc UPB.O:UPSTREAM BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF VEREKITUG IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)UPSTREAM BIO INC - DOSES FIRST PATIENT IN PHASE 2 COPD TRIALReuters
Tue, Jul 8
Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial
July 8 (Reuters) - ProKidney Corp PROK.O:PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETESPROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMEN...Reuters
Tue, Jul 8
Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
July 8 (Reuters) - Adagene Inc 978y.F:ADAGENE INC - PARTNERS WITH CONJUGATEBIO FOR ANTIBODY DRUG CONJUGATE DEVELOPMENTADAGENE INC - TO RECEIVE UNDISCLOSED UPFRONT AND ROYALTY PAYMENTSADAGENE INC - RETAINS NON-ADC RIGHTS TO PARTNERED ANTIBODYFurther company coverage: [978y.F]Reuters
Tue, Jul 8
Eton Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Et-600
July 8 (Reuters) - Eton Pharmaceuticals Inc ETON.O:ETON PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ET-600 (DESMOPRESSIN ORAL SOLUTION)ETON PHARMACEUTICALS INC - NDA TARGET ACTION DATE SET FOR FEBRUARY 25, 2026ETON PHARMACEUTICALS INC - ET-600 HAS PATENT PROTECTION THROUGH 2...Reuters
Tue, Jul 8
